Renal function during vasoactive intestinal peptide (VIP) infusions in normal man and patients with liver disease.
VIP containing nerves are present in the kidney and plasma VIP levels are elevated in cardiac failure and severe liver disease. We studied the effects of intravenous VIP; 6 pmol kg-1 min-1 on 6 normal subjects and 3 patients with liver disease. In normal subjects VIP produced flushing and significant rises in heart rate and pulse pressure but the clearance rates of paraaminohippurate and creatinine did not change significantly. Urine flow fell to about 1/3 and the rate of excretion of electrolytes (except phosphate) fell to about a half of control values. Plasma renin activity rose about 3-fold and there were significant rises in haematocrit and the plasma concentrations of solids, calcium and phosphate. The patients with liver disease responded similarly. Elevated plasma VIP could contribute to salt and water retention in disease states.
D000328:Adult; D000450:Aldosterone / Q000097:blood; D001794:Blood Pressure / Q000187:drug effects; D004573:Electrolytes / Q000652:urine; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007668:Kidney / Q000187:drug effects* / Q000502:physiology / Q000503:physiopathology; D008107:Liver Diseases / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D012016:Reference Values; D012079:Renal Circulation / Q000187:drug effects; D012083:Renin / Q000097:blood; D014660:Vasoactive Intestinal Peptide / Q000097:blood
D004573:Electrolytes; D014660:Vasoactive Intestinal Peptide; D000450:Aldosterone; D012083:Renin